Androgen-independent prostate cancer: Target evolution and disease dynamics

Charles J. Ryan; Eric J. Small

doi:10.1016/j.ddmec.2004.10.005

Androgen-independent prostate cancer: Target evolution and disease dynamics

Charles J. Ryan
, Eric J. Small

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.

Original language	English (US)
Pages (from-to)	223-228
Number of pages	6
Journal	Drug Discovery Today: Disease Mechanisms
Volume	1
Issue number	2
DOIs	https://doi.org/10.1016/j.ddmec.2004.10.005
State	Published - Nov 2004
Externally published	Yes

Bibliographical note

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1016/j.ddmec.2004.10.005

Find It

Find It at U of M Libraries

Cite this

@article{b1449a98965e42c9b270ee2431bc0a8e,

title = "Androgen-independent prostate cancer: Target evolution and disease dynamics",

abstract = "Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.",

author = "Ryan, \{Charles J.\} and Small, \{Eric J.\}",

year = "2004",

month = nov,

doi = "10.1016/j.ddmec.2004.10.005",

language = "English (US)",

volume = "1",

pages = "223--228",

journal = "Drug Discovery Today: Disease Mechanisms",

issn = "1740-6765",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Androgen-independent prostate cancer

T2 - Target evolution and disease dynamics

AU - Ryan, Charles J.

AU - Small, Eric J.

PY - 2004/11

Y1 - 2004/11

N2 - Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.

AB - Prostate cancer is a biologically diverse disease. The hallmark of the disease is its ability to regress, and ultimately regrow, following testosterone deprivation (hormone therapy). Recent developments have yielded new insights into the biological mechanisms of androgen independent growth. In turn, novel therapies directed at these mechanisms, including adrenal androgens, the insulin-like growth factors and transforming growth factor-beta, are being pursued in clinical trials.

UR - https://www.scopus.com/pages/publications/23744471267

UR - https://www.scopus.com/pages/publications/23744471267#tab=citedBy

U2 - 10.1016/j.ddmec.2004.10.005

DO - 10.1016/j.ddmec.2004.10.005

M3 - Review article

AN - SCOPUS:23744471267

SN - 1740-6765

VL - 1

SP - 223

EP - 228

JO - Drug Discovery Today: Disease Mechanisms

JF - Drug Discovery Today: Disease Mechanisms

IS - 2

ER -

Androgen-independent prostate cancer: Target evolution and disease dynamics

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this